explore -WSS

explore

author：hotspot 2025-10-02 21:04:25 - browse：29469

Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Biogen Alzheimer’s drug launch off to slow start

WSS

R1 RCM gets $5.8 billion buyout offer from private equity firm

Obesity drugs seen as possible treatment for liver disease MASH

New documents shed light on MD Anderson Cancer Institute feud

NIH study of ME/CFS points to clear biological hallmarks

Alabama frozen embryo ruling has major implications for IVF clinics

Doctors' information doesn't help them choose wisely when sick

entertainment

explore

explore

Wildfire smoke exposes gaps in outdoor worker protections

Why palliative psychiatry is worth discussing

Anesthesiologist group: stop taking Ozempic before surgery

Private equity deals in Medicare Advantage declines

After affirmative action ruling, medical educators look to 'holistic review'

Gilead might be held responsible for not developing a drug

Medicare details structure of new drug price negotiation program

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Bright Health sells Medicare Advantage business to Molina

Doctors' information doesn't help them choose wisely when sick

focus

Alabama IVF ruling threatens families facing fatal genetic disease

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

A solution to the after

The Readout: Gilead, Bernie Sanders, and other pharma news

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Industry veterans launch new biotech VC with $310M

hotspot

knowledge

hotspot

leisure time